Cortagen: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 8 sources cited

Overview

Cortagen is a Khavinson bioregulator peptide that targets cerebral cortex tissue, supporting cognitive function, neuroprotection, and cortical neuron health. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it is proposed to modulate gene expression in cortical neurons; the published studies are in rat nerve-injury and brain-ischemia models, mouse heart tissue and cell cultures, with no controlled trial of memory, attention or processing speed. It is used in Russian gerontological practice for age-related cognitive decline and as part of comprehensive brain health protocols.

Mechanism of Action

Cortagen is proposed to interact with chromatin in cortical neurons, modulating the transcription of genes involved in synaptic plasticity, neurotransmitter synthesis, and cellular defense against oxidative and excitotoxic stress. The published findings are narrower: Cortagen activated chromatin in cultured blood cells from elderly people; changed the expression of 110 known genes in mouse heart; lowered lipid peroxidation products in rat serum and cerebral cortex, while antioxidant activity fell rather than rose; and sped nerve fiber regrowth after sciatic nerve injury in rats. Effects on BDNF, choline acetyltransferase (ChAT), dendritic spines or apoptosis in neurons have not been reported. Like other Khavinson bioregulators, Cortagen is proposed to work by restoring tissue-specific peptide levels that decline with aging, shifting cortical neuron gene expression toward a younger, more functional phenotype. This approach is fundamentally restorative rather than stimulatory — it doesn't force enhanced cognition through receptor agonism but rather supports the brain's innate cognitive capacity.

Cortagen Benefits: What the Research Shows

  • In rats, 10 days of Cortagen after sciatic nerve injury raised nerve fiber growth rate by 27% and conduction velocity by 40% (Bulletin of Experimental Biology and Medicine, 2000), and the developers state that it aided peripheral nerve recovery in humans. No published trial reports cognitive test scores in elderly patients given Cortagen.
  • In rats with chronic brain ischemia, Cortagen sped recovery of behavior and prevented excess lipid peroxidation in brain tissue (Eksperimental'naia i klinicheskaia farmakologiia, 2011).
  • Cortagen was designed from the amino acid analysis of Cortexin, a brain-cortex extract with a longer clinical record in Russia; that record does not extend to Cortagen, for which no human safety study is indexed in PubMed.
  • Fluorescently labeled short peptides entered HeLa cells and their nuclei in culture (Biochemistry (Moscow), 2011); no pharmacokinetic study showing that Cortagen crosses the blood-brain barrier was found.

Cortagen Dosage

  • Standard dose: 10 mg subcutaneous injection daily.
  • Typical cycle: 10–20 days.
  • Repeat every 3–6 months for ongoing cognitive support.
  • Often combined with Pinealon (pineal gland bioregulator) for comprehensive brain and sleep support.
  • Can be used alongside nootropic peptides (Semax, Selank) which work through different mechanisms — Cortagen provides epigenetic foundation while nootropics provide acute cognitive enhancement.
  • No food timing restrictions.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Cortagen Side Effects & Safety

Known Side Effects

  • Injection site reactions — mild and uncommon.
  • CNS side effects have not been studied; no published human study of Cortagen reports adverse-event data.
  • Drug interactions with neurological or psychiatric medications have not been studied.
  • Short treatment cycles limit any theoretical risks.

Safety Profile

Cortagen's safety in humans has not been established. No clinical safety, toxicology or pharmacokinetic study of Cortagen is indexed in PubMed; the published work is in rats, mice and cell cultures from a small number of Russian groups. Interactions with cholinesterase inhibitors (donepezil, rivastigmine), memantine, or other cognitive medications have not been studied, and neither have effects on alertness or sedation. Contraindications are limited to hypersensitivity and pregnancy/breastfeeding. Effects on seizure threshold have not been studied, so safety in seizure disorders is unknown.

What to Expect

Days 1–10: No immediate cognitive effects. Any interaction with cortical neuron gene regulation is proposed, not measured in people. Days 11–20: Epigenetic modulation is establishing. Some users report subtle improvements in mental clarity or reduced brain fog toward the end of the cycle. Weeks 3–8 (post-cycle): Users describe improved memory recall, faster processing, better sustained attention and clearer thinking. These reports are anecdotal; no controlled study has measured cognition with Cortagen. Months 2–6: Benefits persist throughout the inter-cycle period. Repeat cycles every 3–6 months maintain and accumulate the cognitive benefits. Long-term users of bioregulator protocols report sustained cognitive preservation compared to age-matched peers.

Common Stacks

Storage & Handling

Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution, refrigerate and use within 20 days. Unreconstituted powder shelf life: 24 months. Oral capsules: room temperature, cool and dry.

Pricing & Available Variants

$45price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro Endocrinol Lett. 2004.
  2. Turchaninova LN, Kolosova LI, Malinin VV, et al. Effect of tetrapeptide cortagen on regeneration of sciatic nerve. Bull Exp Biol Med. 2000.
  3. Zarubina IV, Shabanov PD. Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia. Eksp Klin Farmakol. 2011.
  4. Kozina LS. Effects of bioactive tetrapeptides on free-radical processes. Bull Exp Biol Med. 2007.
  5. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004.
  6. Khavinson VKh, Malinin VV, Chalisova NI, et al. Tissue-specific action of peptides in tissue culture of rats of various ages. Adv Gerontol. 2002.
  7. Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age. Adv Gerontol. 2013.
  8. Fedoreyeva LI, Kireev II, Khavinson VKh, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011.

Related Peptides

Track Cortagen in Your Protocol

Log your Cortagen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free